Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rossmax InternationalROCO:4121 -0.38%60 Debt-to-EBITDA is 4.45 as of Jun. 2026, which is 15% above its 10-year median of 3.88. GuruFocus rates ROCO:4121 with a GF Score™ of 60/100 and a GF Value™ of NT$17.62 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 478 Medical Devices & Instruments companies, Rossmax International ranks worse than 79.29% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Rossmax International's Debt-to-EBITDA or its related term are showing as below:
ROCO:4121'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.94 Med: 3.88 Max: 4.36
Current: 4.29
During the past 13 years, the highest Debt-to-EBITDA Ratio of Rossmax International was 4.36. The lowest was 1.94. And the median was 3.88.
ROCO:4121's Debt-to-EBITDA is ranked worse than 79.29% of 478
companies
in the Medical Devices & Instruments industry
Industry Median: 1.65
vs ROCO:4121: 4.29
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Rossmax International Debt-to-EBITDA Related Terms
Rossmax International Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Rossmax International's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4121 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Rossmax International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rossmax International Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rossmax International's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rossmax International's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Rossmax International (ROCO:4121) has a Debt-to-EBITDA of 4.45 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Rossmax International. This is 15% above median its historical median of 3.88. Over the past decade, Rossmax International's Debt-to-EBITDA has ranged from 1.94 to 4.36. According to the industry distribution chart, Rossmax International ranks #379 out of 478 companies in the Medical Devices & Instruments industry, placing it in the top 79.3%.
Is Rossmax International's Debt-to-EBITDA too high?
Rossmax International's current Debt-to-EBITDA of 4.45 is 15% above median its 10-year median of 3.88. Over the past 10 years, this metric has ranged from a low of 1.94 to a high of 4.36. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.65. Rossmax International's value of 4.45 is 169.7% above this industry median. Based on the distribution chart, Rossmax International ranks #379 out of 478 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Rossmax International has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rossmax International's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Rossmax International ranks #379 out of 478 companies for Debt-to-EBITDA. This places Rossmax International in the lower half of its industry. The industry median Debt-to-EBITDA is 1.65. Rossmax International's value of 4.45 is 169.7% above this benchmark. Historically, Rossmax International's own Debt-to-EBITDA has ranged from 1.94 to 4.36 over the past decade. While the company's 10-year median is 3.88 vs. the industry median of 1.65, Rossmax International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.65, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rossmax International's current Debt-to-EBITDA of 4.45 is 169.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Rossmax International. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rossmax International's current Debt-to-EBITDA is 4.45, which is 15% above median its own 10-year median of 3.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rossmax International stock overvalued right now?
Based on GuruFocus' analysis, Rossmax International (ROCO:4121) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$17.62, compared to a current price of NT$13.15 — trading 25.4% below its estimated fair value. The current Debt-to-EBITDA is 4.45, which is 15% above median its 10-year median of 3.88 and 169.7% above the Medical Devices & Instruments industry median of 1.65. Rossmax International's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Rossmax International (ROCO:4121), the current Debt-to-EBITDA is 4.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rossmax International (ROCO:4121) Overvalued in 2026?
Based on GuruFocus' analysis, Rossmax International stock appears to be undervalued.
The current stock price of NT$13.15 is trading 25.4% below its estimated GF Value™ of NT$17.62.
GuruFocus considers Rossmax International to be Modestly Undervalued.
Key valuation signals for ROCO:4121:
Debt-to-EBITDA: 4.45 (15% above median its 10-year median of 3.88)
GF Value™: NT$17.62 vs. price of NT$13.15 (25.4% below fair value)
Industry Position: 169.7% above the Medical Devices & Instruments median (#379 of 478)
No single metric tells the full story. See the ROCO:4121 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rossmax International Ltd is mainly engaged in medical equipment manufacturing, wholesale or retail, and the medicine and cosmetics channels. The group has three reportable departments: the medical device department, the retail channel department, and the investment department. The medical device department manufactures various types of medical supplies. The retail channel department is engaged in the retail of cosmetics, medical equipment, food products, and beverages. Geographically, it derives key revenue from the Taiwan region and the rest from Iraq, Algeria, the U.S.A, the U.A.E, Malaysia, Iran, Kazakhstan, South Korea, Norway, Croatia, Tunisia, and Other.
60GF Score
Get the complete analysis for ROCO:4121
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4121 has been successfully added to your 
